Somatostatin, neuronal vulnerability and behavioral emotionality

Molecular Psychiatry

Volumn 20, Issue 3, 2015, Pages 377-387

  Lin, L C ^a   Sibille, E ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CORTISTATIN; GLUTAMATE DECARBOXYLASE 67; INITIATION FACTOR 2; SOMATOSTATIN; TRANSCRIPTOME; 7-METHYL-5-(1-((3-(TRIFLUOROMETHYL)PHENYL)ACETYL)-2,3-DIHYDRO-1H-INDOL-5-YL)-7H-PYRROLO(2,3-D)PYRIMIDIN-4-AMINE; ADENINE; ANTIDEPRESSANT AGENT; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; GREEN FLUORESCENT PROTEIN; INDOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; EMOTIONALITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; INTERNEURON; KNOCKOUT MOUSE; LASER CAPTURE MICRODISSECTION; MALE; MOUSE; NERVE CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING; PYRAMIDAL NERVE CELL; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CINGULATE GYRUS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; MENTAL STRESS; METABOLISM; MOOD DISORDERS; PATHOLOGY; TRANSGENIC MOUSE;

ADENINE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; DISEASE MODELS, ANIMAL; EUKARYOTIC INITIATION FACTOR-2; FEMALE; GENE EXPRESSION REGULATION; GLUTAMATE DECARBOXYLASE; GREEN FLUORESCENT PROTEINS; GYRUS CINGULI; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOOD DISORDERS; NEURONS; SIGNAL TRANSDUCTION; SOMATOSTATIN; STRESS, PSYCHOLOGICAL; TRANSCRIPTOME;

EID: 84924748164     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.184     Document Type: Article

References (85)

1. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003; 60: 929-937
2. WHO World Health Organization-The Global Burden of Disease-2004 Update. Geneva, Switzerland: WHO Library, 2008
3. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2012; 18: 595-606
4. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-Term outcomes in depressed outpatients requiring one or several treatment steps: a STAR.D report. Am J Psychiatry 2006; 163: 1905-1917
5. Lin LC, Sibille E. Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target? Front Pharmacol 2013; 4: 110
6. Martel G, Dutar P, Epelbaum J, Viollet C. Somatostatinergic systems: an update on brain functions in normal and pathological aging. Front Endocrinol (Lausanne) 2012; 3: 154
7. Tripp A, Oh H, Guilloux JP, Martinowich K, Lewis DA, Sibille E. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry 2012; 169: 1194-1202
8. Sibille E, Morris HM, Kota RS, Lewis DA. GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol 2011; 14: 721-734
9. Guilloux JP, Douillard-Guilloux G, Kota R, Wang X, Gardier AM, Martinowich K, et al. Molecular evidence for BDNF- And GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 2012; 17: 1130-1142
10. Tripp A, Kota RS, Lewis DA, Sibille E. Reduced somatostatin in subgenual anterior cingulate cortex in major depression. Neurobiol Dis 2011; 42: 116-124
11. Hendry SH, Jones EG, Emson PC. Morphology, distribution, and synaptic relations of somatostatin- And neuropeptide Y-immunoreactive neurons in rat and monkey neocortex. J Neurosci 1984; 4: 2497-2517
12. Melchitzky DS, Lewis DA. Dendritic-Targeting GABA neurons in monkey prefrontal cortex: comparison of somatostatin- And calretinin-immunoreactive axon terminals. Synapse 2008; 62: 456-465
13. Xu X, Roby KD, Callaway EM. Immunochemical characterization of inhibitory mouse cortical neurons: three chemically distinct classes of inhibitory cells. J Comp Neurol 2010; 518: 389-404
14. Gentet LJ, Kremer Y, Taniguchi H, Huang ZJ, Staiger JF, Petersen CC. Unique functional properties of somatostatin-expressing GABAergic neurons in mouse barrel cortex. Nat Neurosci 2012; 15: 607-612
15. Le Magueresse C, Monyer H. GABAergic interneurons shape the functional maturation of the cortex. Neuron 2013; 77: 388-405
16. DeFelipe J, Lopez-Cruz PL, Benavides-Piccione R, Bielza C, Larranaga P, Anderson S, et al. New insights into the classification and nomenclature of cortical GABAergic interneurons. Nat Rev Neurosci 2013; 14: 202-216
17. Zeyda T, Diehl N, Paylor R, Brennan MB, Hochgeschwender U. Impairment in motor learning of somatostatin null mutant mice. Brain Res 2001; 906: 107-114
18. Agren H, Lundqvist G. Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 1984; 9: 233-248
19. Molchan SE, Lawlor BA, Hill JL, Martinez RA, Davis CL, Mellow AM, et al. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry 1991; 29: 1110-1118
20. Kling MA, Rubinow DR, Doran AR, Roy A, Davis CL, Calabrese JR, et al. Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indices of corticotropinreleasing hormone and cortisol secretion. Neuroendocrinology 1993; 57: 79-88
21. Molchan SE, Hill JL, Martinez RA, Lawlor BA, Mellow AM, Rubinow DR, et al. CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-Adrenal axis and clinical measures. Psychoneuroendocrinology 1993; 18: 509-519
22. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005; 4: 141-194
23. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
24. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68
25. Stengel A, Rivier J, Tache Y. Central actions of somatostatin-28 and oligosomatostatin agonists to prevent components of the endocrine, autonomic and visceral responses to stress through interaction with different somatostatin receptor subtypes. Curr Pharm Des 2013; 19: 98-105
26. Fisher DA, Brown MR. Somatostatin analog: plasma catecholamine suppression mediated by the central nervous system. Endocrinology 1980; 107: 714-718
27. Brown MR, Rivier C, Vale W. Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology 1984; 114: 1546-1549
28. Stengel A, Goebel-Stengel M, Wang L, Luckey A, Hu E, Rivier J, et al. Central administration of pan-somatostatin agonist ODT8-SST prevents abdominal surgery-induced inhibition of circulating ghrelin, food intake and gastric emptying in rats. Neurogastroenterol Motil 2011; 23: e294-e308
29. Keller MC, Neale MC, Kendler KS. Association of different adverse life events with distinct patterns of depressive symptoms. Am J Psychiatry 2007; 164: 1521-1529, quiz 1622
30. Vezzani A, Hoyer D. Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. Eur J Neurosci 1999; 11: 3767-3776
31. Ponomarev I, Rau V, Eger EI, Harris RA, Fanselow MS. Amygdala transcriptome and cellular mechanisms underlying stress-enhanced fear learning in a rat model of posttraumatic stress disorder. Neuropsychopharmacology 2010; 35: 1402-1411
32. Martinowich K, Schloesser RJ, Jimenez DV, Weinberger DR, Lu B. Activitydependent brain-derived neurotrophic factor expression regulates cortistatininterneurons and sleep behavior. Mol Brain 2011; 4: 11
33. Glorioso C, Sabatini M, Unger T, Hashimoto T, Monteggia LM, Lewis DA, et al. Specificity and timing of neocortical transcriptome changes in response to BDNF gene ablation during embryogenesis or adulthood. Mol Psychiatry 2006; 11: 633-648
34. Grosse G, Djalali S, Deng DR, Holtje M, Hinz B, Schwartzkopff K, et al. Area-specific effects of brain-derived neurotrophic factor (BDNF) genetic ablation on various neuronal subtypes of the mouse brain. Brain Res Dev Brain Res 2005; 156: 111-126
35. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606
36. Albrecht A, Thiere M, Bergado-Acosta JR, Poranzke J, Muller B, Stork O. Circadian modulation of anxiety: a role for somatostatin in the amygdala. PLoS One 2013; 8: e84668
37. Yeung M, Engin E, Treit D. Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-Amygdalar and intra-septal microinfusions. Psychopharmacology (Berl) 2011; 216: 557-567
38. Yeung M, Treit D. The anxiolytic effects of somatostatin following intra-septal and intra-Amygdalar microinfusions are reversed by the selective sst2 antagonist PRL2903. Pharmacol Biochem Behav 2012; 101: 88-92
39. Soumier A, Sibille E. Opposing effects of acute versus chronic blockade of frontal cortex somatostatin-positive inhibitory neurons on behavioral emotionality in mice. Neuropsychopharmacology 2014; 39: 2252-2262
40. Taniguchi H, He M, Wu P, Kim S, Paik R, Sugino K, et al. A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron 2011; 71: 995-1013
41. Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G, et al. Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009; 34: 1363-1380
42. Sibille E, Pavlides C, Benke D, Toth M. Genetic inactivation of the serotonin(1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety. J Neurosci 2000; 20: 2758-2765
43. Guilloux JP, Seney M, Edgar N, Sibille E. Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sex. J Neurosci Methods 2011; 197: 21-31
44. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009; 62: 479-493
45. Lin LC, Lewis DA, Sibille E. A human-mouse conserved sex bias in amygdala gene expression related to circadian clock and energy metabolism. Mol Brain 2011; 4: 18
46. Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, et al. Suppression of eIF2alpha kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat Neurosci 2013; 16: 1299-1305
47. Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med 2013; 5: 206ra138
48. Kim HJ, Raphael AR, Ladow ES, McGurk L, Weber RA, Trojanowski JQ, et al. Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet 2014; 46: 152-160
49. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-389
50. Sibille E, Wang Y, Joeyen-Waldorf J, Gaiteri C, Surget A, Oh S, et al. A molecular signature of depression in the amygdala. Am J Psychiatry 2009; 166: 1011-1024
51. Nollet M, Le Guisquet AM, Belzung C. Models of depression: unpredictable chronic mild stress in mice. Curr Protoc Pharmacol 2013 (Chapter 5, Unit 5): 65
52. Scalera G, Tarozzi G. Somatostatin administration modifies food intake, body weight, and gut motility in rat. Peptides 1998; 19: 991-997
53. Ricci GL, Fevery J. Somatostatin inhibits the effect of secretin on bile flow and on hepatic bilirubin transport in the rat. Gut 1989; 30: 1266-1269
54. de Lecea L, del Rio JA, Criado JR, Alcantara S, Morales M, Danielson PE, et al. Cortistatin is expressed in a distinct subset of cortical interneurons. J Neurosci 1997; 17: 5868-5880
55. Viollet C, Lepousez G, Loudes C, Videau C, Simon A, Epelbaum J. Somatostatinergic systems in brain: networks and functions. Mol Cell Endocrinol 2008; 286: 75-87
56. de Lecea L. Cortistatin-functions in the central nervous system. Mol Cell Endocrinol 2008; 286: 88-95
57. Nagata T, Ilieva H, Murakami T, Shiote M, Narai H, Ohta Y, et al. Increased ER stress during motor neuron degeneration in a transgenic mouse model of amyotrophic lateral sclerosis. Neurol Res 2007; 29: 767-771
58. Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 2014; 30: 523-530
59. Ardayfio P, Kim KS. Anxiogenic-like effect of chronic corticosterone in the lightdark emergence task in mice. Behav Neurosci 2006; 120: 249-256
60. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 2000; 6: 1099-1108
61. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, et al. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 2012; 485: 507-511
62. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005; 307: 935-939
63. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[ 2,3-d]pyrimidin-4-Amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem 2012; 55: 7193-7207
64. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809
65. Carroll BJ, Schroeder K, Mukhopadhyay S, Greden JF, Feinberg M, Ritchie J, et al. Plasma dexamethasone concentrations and cortisol suppression response in patients with endogenous depression. J Clin Endocrinol Metab 1980; 51: 433-437
66. Burgus R, Ling N, Butcher M, Guillemin R. Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. Proc Natl Acad Sci USA 1973; 70: 684-688
67. de Kloet ER, Sarabdjitsingh RA. Everything has rhythm: focus on glucocorticoid pulsatility. Endocrinology 2008; 149: 3241-3243
68. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 2003; 54: 515-528
69. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156: 675-682
70. Brody AL, Saxena S, Mandelkern MA, Fairbanks LA, Ho ML, Baxter LR. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biol Psychiatry 2001; 50: 171-178
71. Kim SS, Wang H, Li XY, Chen T, Mercaldo V, Descalzi G, et al. Neurabin in the anterior cingulate cortex regulates anxiety-like behavior in adult mice. Mol Brain 2011; 4: 6
72. Ramirez JL, Mouchantaf R, Kumar U, Otero Corchon V, Rubinstein M, Low MJ, et al. Brain somatostatin receptors are up-regulated in somatostatin-deficient mice. Mol Endocrinol 2002; 16: 1951-1963
73. Cammalleri M, Cervia D, Dal Monte M, Martini D, Langenegger D, Fehlmann D, et al. Compensatory changes in the hippocampus of somatostatin knockout mice: upregulation of somatostatin receptor 2 and its function in the control of bursting activity and synaptic transmission. Eur J Neurosci 2006; 23: 2404-2422
74. Pothion S, Bizot JC, Trovero F, Belzung C. Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav Brain Res 2004; 155: 135-146
75. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987; 93: 358-364
76. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-529
77. Valdes P, Mercado G, Vidal RL, Molina C, Parsons G, Court FA, et al. Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc Natl Acad Sci USA 2014; 111: 6804-6809
78. Leitman J, Barak B, Benyair R, Shenkman M, Ashery U, Hartl FU, et al. ER stressinduced eIF2-Alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin. PLoS One 2014; 9: e90803
79. Saxena S, Cabuy E, Caroni P. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci 2009; 12: 627-636
80. Hetz C, Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci 2014; 15: 233-249
81. Calfon M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP, et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002; 415: 92-96
82. Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, et al. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat Genet 2003; 35: 171-175
83. Hayashi A, Kasahara T, Kametani M, Kato T. Attenuated BDNF-induced upregulation of GABAergic markers in neurons lacking Xbp1. Biochem Biophys Res Commun 2008; 376: 758-763
84. Zhu PJ, Huang W, Kalikulov D, Yoo JW, Placzek AN, Stoica L, et al. Suppression of PKR promotes network excitability and enhanced cognition by interferongamma-mediated disinhibition. Cell 2011; 147: 1384-1396
85. Trinh MA, Kaphzan H, Wek RC, Pierre P, Cavener DR, Klann E. Brain-specific disruption of the eIF2alpha kinase PERK decreases ATF4 expression and impairs behavioral flexibility. Cell Rep 2012; 1: 676-688